CORONA Remedies Limited (BOM:544644)

CORONA Remedies Statistics

Total Valuation

CORONA Remedies has a market cap or net worth of INR 91.69 billion. The enterprise value is 91.78 billion.

Market Cap	91.69B
Enterprise Value	91.78B

Important Dates

The next estimated earnings date is Thursday, May 21, 2026.

Earnings Date	May 21, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	61.16M
Shares Outstanding	n/a
Shares Change (YoY)	-0.03%
Shares Change (QoQ)	-0.09%
Owned by Insiders (%)	69.00%
Owned by Institutions (%)	6.24%
Float	6.17M

Valuation Ratios

The trailing PE ratio is 53.51 and the forward PE ratio is 41.42.

PE Ratio	53.51
Forward PE	41.42
PS Ratio	6.82
PB Ratio	13.90
P/TBV Ratio	18.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	53.56
EV / Sales	6.83
EV / EBITDA	31.44
EV / EBIT	36.87
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.10
Debt / EBITDA	0.21
Debt / FCF	n/a
Interest Coverage	32.95

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	27.81%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	2.99M
Profits Per Employee	380,764
Employee Count	4,500
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, CORONA Remedies has paid 579.49 million in taxes.

Income Tax	579.49M
Effective Tax Rate	25.27%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	1,546.90
200-Day Moving Average	n/a
Relative Strength Index (RSI)	40.67
Average Volume (20 Days)	3,401

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CORONA Remedies had revenue of INR 13.44 billion and earned 1.71 billion in profits. Earnings per share was 28.02.

Revenue	13.44B
Gross Profit	10.86B
Operating Income	2.49B
Pretax Income	2.29B
Net Income	1.71B
EBITDA	2.88B
EBIT	2.49B
Earnings Per Share (EPS)	28.02

Balance Sheet

The company has 539.60 million in cash and 627.10 million in debt, with a net cash position of -87.50 million.

Cash & Cash Equivalents	539.60M
Total Debt	627.10M
Net Cash	-87.50M
Net Cash Per Share	n/a
Equity (Book Value)	6.60B
Book Value Per Share	107.80
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	395.62M
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 80.79%, with operating and profit margins of 18.51% and 12.75%.

Gross Margin	80.79%
Operating Margin	18.51%
Pretax Margin	17.06%
Profit Margin	12.75%
EBITDA Margin	21.45%
EBIT Margin	18.51%
FCF Margin	n/a

Dividends & Yields

CORONA Remedies does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.03%
Shareholder Yield	0.03%
Earnings Yield	1.87%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2